GlassScriptPhysician profile
Carl L Rouch
NPI 1124099650
$3,479.65
in general payments reported to CMS, 2019-2025
26 companies · $233 in 2025
The $233 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $388 · 2021: $283 · 2022: $380 · 2023: $519 · 2024: $1,391 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,652 · Travel and Lodging: $492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,651.93 |
| Travel and Lodging | $491.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $558.30 | 2024 | Indigo System |
| Shockwave Medical, INC | $444.36 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $356.56 | 2022-2025 | Symplicity G3 |
| Boston Scientific Corporation | $269.38 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $227.80 | 2020-2024 | Lifevest |
| Impulse Dynamics (USA) INC. | $216.22 | 2023 | Optimizer |
| Abiomed | $155.55 | 2019-2023 | Impella |
| Astrazeneca Pharmaceuticals LP | $145.48 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $132.86 | 2019-2024 | Camzyos |
| Janssen Pharmaceuticals, INC | $132.13 | 2020-2024 | Xarelto |
| Philips North America LLC | $131.30 | 2022-2025 | (Ck4) Mcot, Extended Holter |
| Novartis Pharmaceuticals Corporation | $117.13 | 2019-2023 | |
| Amgen INC. | $101.61 | 2019-2024 | Repatha |
| Bard Peripheral Vascular, INC. | $99.80 | 2021 | |
| Medtronic Vascular, INC. | $78.12 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $57.24 | 2019-2021 | |
| Cardiva Medical, INC. | $36.09 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Integra Lifesciences Corporation | $33.42 | 2025 | Integra, Integra Dermal Regeneration Template, Surgimend |
| Regeneron Healthcare Solutions, INC. | $33.33 | 2019 | |
| Chiesi USA, INC. | $27.77 | 2022 | |
| Vital Connect, INC | $24.94 | 2025 | Vitalpatch Rtm |
| Cardiovascular Systems INC. | $23.48 | 2022 | |
| Atricure, INC. | $22.71 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Bardy Diagnostics, INC. | $20.66 | 2021 | |
| Tactile Systems Technology INC | $19.39 | 2021 | |
| Merck Sharp & Dohme LLC | $14.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Rouch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.